Data Sheet (Cat.No.TMPY-05568)

TargetMol

BCMA/TNFRSF17 Protein, Human (His & hFc), PE conjugated

General Information

Synonyms: BCMA;TNFRSF13A;tumor necrosis factor receptor superfamily member 17;BCM;CD269

Protein Construction: Recombinant human BCMA/TNFRSF17 (NP_001183.2, extracellular domain, Met 1-Ala 54) are conjugated with PE under optimum conditions, the unreacted PE was removed.

Species: Human

Expression Host: HEK293 Cells

Accession: NP_001183.2

QC Testing

Biological Activity: Tested by Flow cytometric analysis of anti-BCMA CAR expression.

Formulation: Aqueous solution containing 0.5% BSA and 0.03% Proclin 300

Preparation and Storage

Stability & Storage:

This reagent is stable for 6 months when stored at 2°C-8°C. Protected from prolonged exposure to light. Do not freeze!

Actual storage temperature shall be subject to the COA.

Shipping:

Proteins are shipped with blue ice.

Protein Background

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

Reference

Novak AJ,et al.(2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 103 (2): 689-94.

O'Connor BP,et al.(2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 199 (1): 91-8.

Moser K,et al.(2006) Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol. 18(3): 265-70.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481